Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Price Performance

Shares of ACOR opened at $0.66 on Monday. Acorda Therapeutics has a 12-month low of $0.61 and a 12-month high of $24.20. The business’s fifty day moving average is $10.56 and its 200 day moving average is $11.97. The company has a quick ratio of 0.26, a current ratio of 0.33 and a debt-to-equity ratio of 3.07. The stock has a market cap of $819,640.00, a P/E ratio of 0.00 and a beta of 1.40.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.